Objective of the research – to evaluate effect of angiotensin converting enzyme inhibitors (ACEI) on uric level of profibrogenic factors and renoprotective effects in dynamics of treatment of children with vesicoureteral reflux (VUR). The study group included 62 children aged 1–14 years (5,69±0,44 years, 83,9% girls), with varying degrees of VUR and reflux nephropathy (RN), treated with Enalapril in a dose of 0,2 mg/kg 1 time a day for 6 months as renoprotective therapy. Treatment efficacy was evaluated by static neghroscintigraphy with DMSA, level of urea and creatinine in the blood, glomerular filtration rate (GFR), Zimnitsky test and ultrasonography with dopplerography. In treatment dynamics uric level of profibrogenic growth factor (TGFβ1 and AngII), microalbuminuria (MAU) and β₂-microglobulin (β₂MG) were measured. According to study results, within 6 months after treatment with ACEI most patients with RN had decrease in production of growth factors (AngII and TGFβ₁), decrease of microalbuminuria and normalization of urine density in 94,4% of children with 1–2 RN degree and in 85,7% of children with 3–4 RN degree; dopplerographic characteristics improved in 78,8% of cases. In children with 3–4 RN degree ACEI have not led to a significant reduction in growth factors, and in children without ACEI treatment had low resistive indicators, further decline of glomerular filtration rate, increased urinary excretion of profibrogenic growth factors and microproteinuria. Authors recommend Enalapril to treat RN early stages in children with VUR.